C Cipolla

1.1k total citations · 1 hit paper
17 papers, 461 citations indexed

About

C Cipolla is a scholar working on Surgery, Oncology and Cancer Research. According to data from OpenAlex, C Cipolla has authored 17 papers receiving a total of 461 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Surgery, 6 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in C Cipolla's work include Bladder and Urothelial Cancer Treatments (5 papers), Cancer Treatment and Pharmacology (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). C Cipolla is often cited by papers focused on Bladder and Urothelial Cancer Treatments (5 papers), Cancer Treatment and Pharmacology (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). C Cipolla collaborates with scholars based in United States and Italy. C Cipolla's co-authors include Dean F. Bajorin, Samuel A. Funt, Ashley Marie Regazzi, Brooke Kania, Alexandra Snyder, Gopa Iyer, David B. Solit, Hikmat Al‐Ahmadie, Maria I. Carlo and Margaret K. Callahan and has published in prestigious journals such as Journal of Clinical Oncology, JCO Oncology Practice and PubMed.

In The Last Decade

C Cipolla

11 papers receiving 457 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers

2018 374 citations Min Yuen Teo, Kenneth Seier et al. Journal of Clinical Oncology profile →

Peers

C Cipolla

ONCOL

SURGE

PRM

Brooke Kania United States

J. Cheng United States

Saburo Nakashima Japan

Prasanth Reddy United States

Mariel Elena Boyd United States

Aiwen Wu China

S.T. Kim South Korea

A. Tryakin Russia

Byung Woog Kang South Korea

Yawara Funasako Japan

Brooke Kania United States

C Cipolla

324 ×1.0

ONCOL

193 ×1.1

SURGE

154 ×0.9

PRM

130 ×0.9

84 ×1.0

Citations per year, relative to C Cipolla C Cipolla (= 1×) peers Brooke Kania

Countries citing papers authored by C Cipolla

Since Specialization

Citations

This map shows the geographic impact of C Cipolla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C Cipolla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C Cipolla more than expected).

Fields of papers citing papers by C Cipolla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C Cipolla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C Cipolla. The network helps show where C Cipolla may publish in the future.

Co-authorship network of co-authors of C Cipolla

This figure shows the co-authorship network connecting the top 25 collaborators of C Cipolla. A scholar is included among the top collaborators of C Cipolla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C Cipolla. C Cipolla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Afghahi, Anosheh, Yichen Lu, Laura Hester, et al.. (2025). Accrual of historically underrepresented patients with multiple myeloma using centralized screening in a multicenter study.. Journal of Clinical Oncology. 43(16_suppl).

Afghahi, Anosheh, et al.. (2024). A multi-modal EHR-based approach to screen patients for oncology clinical trials.. JCO Oncology Practice. 20(10_suppl). 411–411.

Teo, Min Yuen, Kenneth Seier, Irina Ostrovnaya, et al.. (2018). Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. Journal of Clinical Oncology. 36(17). 1685–1694. 374 indexed citations breakdown →

Cheng, Michael L., Maha Shady, C Cipolla, et al.. (2017). Comparison of somatic mutation profiles from cell free DNA (cfDNA) versus tissue in metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 35(15_suppl). 4533–4533. 3 indexed citations

Teo, Min Yuen, Kenneth Seier, Irina Ostrovnaya, et al.. (2017). DNA damage repair and response (DDR) gene alterations (alt) and response to PD1/PDL1 blockade in platinum-treated metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 35(15_suppl). 4509–4509. 12 indexed citations

Funt, Samuel A., Zhenyu Mu, C Cipolla, et al.. (2017). Evaluation of monocytic myeloid-derived suppressor cell (M-MDSC) frequency in patients with metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 35(6_suppl). 356–356. 1 indexed citations

Carlo, Maria I., Liying Zhang, Diana Mandelker, et al.. (2017). Cancer predisposing germline mutations in patients (pts) with urothelial cancer (UC) of the renal pelvis (R-P), ureter (U) and bladder (B).. Journal of Clinical Oncology. 35(15_suppl). 4510–4510. 14 indexed citations

Funt, Samuel A., Alexandra Snyder, Erik Yusko, et al.. (2016). Correlation of peripheral and intratumoral T-cell receptor (TCR) clonality with clinical outcomes in patients with metastatic urothelial cancer (mUC) treated with atezolizumab.. Journal of Clinical Oncology. 34(15_suppl). 3005–3005. 22 indexed citations

Cipolla, C, et al.. (2012). Il sociologo, le sirene e le pratiche di integrazione, Volume I. BOA (University of Milano-Bicocca). 5–384.

10.

Cipolla, C, et al.. (2012). Il sociologo, le sirene e gli avatar - Volume II. BOA (University of Milano-Bicocca). 5–251. 1 indexed citations

11.

Latteri, M, et al.. (1996). Les tumeurs phyllodes du sein. Nova Science Publishers (Nova Science Publishers, Inc.). 92(2). 105–108. 1 indexed citations

12.

Gebbia, Vittorio, Michele Caruso, Roberto Valenza, et al.. (1994). Vinorelbine plus cisplatinum for the treatment of stage IIIB and IV non small cell lung carcinoma.. PubMed. 14(3B). 1247–9. 28 indexed citations

13.

Cipolla, C, et al.. (1993). Indication et limites du traitement par la L-Thyroxine dans la prophylaxie de la récidive après exérèse chirurgical pour pathologie thyroidienne bénigne a foncionnement normal.. Nova Science Publishers (Nova Science Publishers, Inc.). 89(1). 37–39. 1 indexed citations

14.

Testa, A., Roberto Valenza, C Cipolla, et al.. (1993). Levo folinic acid and 5-fluorouracil plus high dose epidoxorubicin as first line treatment for metastatic breast carcinoma.. PubMed. 13(1). 141–4. 3 indexed citations

15.

Amato, C, C Cipolla, Giuseppa Graceffa, et al.. (1991). [Role of ultrasonography in the diagnosis of carcinoma of the breast].. PubMed. 11(7-8). 435–8.

16.

Cassano, Tommaso, C Cipolla, Giuseppa Graceffa, et al.. (1991). [The role of galactography in the diagnosis of breast diseases. Our experience].. PubMed. 46(18). 967–72. 1 indexed citations

17.

Latteri, M, C Cipolla, Gianni Pantuso, et al.. (1990). [The value and limits of the follow-up in patients operated on for breast carcinoma. Our experience].. PubMed. 45(21-22). 1379–84.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact